A Phase 2 interventional study of TAK-906 Maleate and Metaclopramide in Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-06.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Diabetes Mellitus by Takeda — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · Takeda.
Among the 71 studies in Diabetes Mellitus by Takeda, this one is the 59th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2017, is one of 12 in phase 2, and was the 71st registered.
8,292 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.
Browse Diabetes Mellitus studies →None of the 71 studies in Diabetes Mellitus by Takeda is open now. The open studies under Diabetes Mellitus, anywhere →
Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 19 · Phase 3 47 · Phase 4 7
First in 1997; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 80 across 6,024 interventional studies indexed under Diabetes Mellitus.
Median enrollment 326 across the 66 interventional studies, 193,099 across the 5 observational. Of the 71 that completed or were terminated, 35 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 71 studies in Diabetes Mellitus by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, PK and PD of TAK-906 in participants with Gastroparesis (GP).
The drug being tested in this study is called TAK-906 maleate. TAK-906 maleate is being tested to treat people who have DG or IG. This study will assess the safety, tolerability, PK/PD and food effect of TAK-906 and will determine the effect of TAK-906 on gastric emptying (GE).
The study enrolled a total of 51 participants. This study will be conducted in two parts: Part 1 and Part 2. Part 1 will consist of 48 participants enrolled in 3 active treatment groups and 1 placebo group. Participants in Part 1 will be randomly assigned (by chance, like flipping a coin) to one of the 3 active treatment groups or 1 placebo group-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
All participants who will complete Part 1 of the study will be eligible for enrollment in Part 2. Part 2 consisted of 21 participants who completed Part 1 and were assigned to the 2 open-label treatment groups as follow:
This multi-center trial will be conducted the United States. The overall time to participate in this study is approximately 8 weeks. Participants will make a final visit to the clinic 10-14 days after receiving their last dose of study drug for a follow-up assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible for participation in this trial, the participant must:
Exclusion Criteria
The participant must be excluded from participating in the trial if the participant:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-906 placebo-matching (4x0 mg), capsule, orally, twice daily (BID) on Days 1-8 and once on Day 9 under fasted conditions.
Drug: TAK-906 Maleate Placebo
TAK-906 maleate 1x5 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8, followed by TAK-906 maleate 1x5 mg, capsule, orally once on Day 9 under fasted conditions.
Drug: TAK-906 Maleate
TAK-906 maleate 1x25 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8 followed by TAK-906 maleate 1x25 mg, capsule, orally, once on Day 9 under fasted conditions.
Drug: TAK-906 Maleate
TAK-906 maleate 100 mg (4x25 mg), capsules, orally, BID on Days 1-8 and once a day on Day 9 under fasted conditions.
Drug: TAK-906 Maleate
TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (high fat breakfast), followed by a minimum 7- day washout.
Drug: TAK-906 Maleate
TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions.
Drug: TAK-906 Maleate
Metaclopramide 10 mg, tablet, orally, once, 1 hour prior to breakfast on Day 1 in Part 2.
Drug: Metaclopramide
TAK-906 Maleate Capsules
Metaclopramide Tablets
TAK-906 placebo-matching Capsules
Number of Participants Who Experienced At Least One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is an AE resulting in any of the following outcomes or deemed significant for any following reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event.
Time frame: From Baseline to 14 days after the last dose of study drug (Up to approximately 39 days)
Number of Participants With Markedly Abnormal Laboratory Parameters Values
Clinical Laboratory parameters included tests for chemistry, hematology and urinalysis. Markedly abnormal values during treatment period were categorized as:alanine aminotransferase (ALT)\>3.0 U/L\*upper limit of normal(ULN),albumin\<25 g/L\*lower limit of normal(LLN),alkaline phosphatase \>3.0 U/L\*ULN,aspartate aminotransferase \>3.0 U/L\*ULN,bilirubin \>2 umol/L\*ULN,blood urea nitrogen(BUN) \>10.7 mmol/L,calcium \<1.75 mmol/L, \>2.88 mmol/L,chloride \<75 mmol/L, \>126 mmol/L,creatinine \>177umol/L,gamma glutamyl transferase (GGT) \>3 U/L\*ULN,glucose \<2.8 mmol/L, \>19.4 mmol/L,phosphate \<0.52 mmol/L, \>2.10 mmol/L,potassium\<3 mmol/L, \>6 mmol/L,sodium \<130 mmol/L, \>150 mmol/L,hematocrit (%) \<0.8\*LLN, \>1.2\*ULN,hemoglobin \<0.8 g/L\*LLN, \>1.2 g/L\*ULN,leukocytes \<0.5 (10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN,erythrocytes\<0.8 (10\^12/L)\*LLN, \>1.2(10\^12/L)\*ULN,platelets \<75(10\^9/L), \>600(10\^9/L). Participants with at least 1 markedly abnormal laboratory parameter value is reported.
Time frame: From Baseline to 14 days after the last dose of study drug in Part 1 (Up to approximately 23 days)
Number of Participants With Markedly Abnormal Vital Signs
Vital signs included body temperature, diastolic and systolic blood pressure (mmHg), and heart rate (beats per minute \[bpm\]). Heart rate\<50 bpm and systolic blood pressure \<85 mmHg were considered markedly abnormal.
Time frame: From Baseline to 14 days after the last dose of study drug (Up to approximately 39 days)
Number of Participants With Markedly Abnormal Electrocardiogram (ECG) Values
The 12-lead electrocardiogram (ECG) values outside the range Heart Rate \<50 (beats/min), PR Interval ≤120 (msec), PR Interval ≥200 (msec), QRS Duration ≥120 (msec), QT Interval ≥460 (msec) were considered markedly abnormal.
Time frame: From Baseline to 14 days after the last dose of study drug (Up to approximately 39 days)
Change From Baseline in Serum Prolactin Concentration on Day 1 at Tmax, Time of First Occurrence of Maximum Serum Concentration (Cmax) for TAK-906 Maleate for Part 1
Change in serum prolactin on Day 1 at the Tmax, time of first occurrence of maximum serum concentration (Cmax) relative to Baseline was calculated as a ratio of maximum serum prolactin concentration on Day 1 to serum prolactin concentration at Baseline.
Time frame: Day 1 predose (Baseline), 1 hour and at multiple timepoints (Up to 8 hours) postdose
Change From Baseline in Gastric Emptying Breath Test (GEBT) Gastric Half-emptying Time as Measured by the 13C Spirulina GEBT Following Multiple Dose Administration of TAK-906 Maleate on Day 7 for Part 1
The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE) in adults. The GEBT measures how fast solid food moves from the stomach to the small intestine during the digestive process and aids in the diagnosis of delayed stomach emptying (GP). GE half-emptying time is the time in minutes (min) for half of the ingested solids to leave the stomach. This value was measured by the 13C spirulina GEBT.
Time frame: Baseline and Day 7
Change From Baseline in Gastric Emptying Breath Test (GEBT) Gastric Half-emptying Time Following Single Dose Administration of TAK-906 Maleate as Measured by the 13C Spirulina GEBT on Day 1
The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE) in adults. The GEBT measures how fast solid food moves from the stomach to the small intestine during the digestive process and aids in the diagnosis of delayed stomach emptying (GP). GE half-emptying time is the time in minutes (min) for half of the ingested solids to leave the stomach. This value was measured by the 13C spirulina GEBT.
Time frame: Baseline and Day 1 of Part 1
Percent Change From Baseline in Gastric Emptying (GE) Time as Measured by the SmartPill on Day 7 for Part 1
SmartPill is an ingestible capsule that measures pressure, potential of hydrogen (pH) and temperature as it travels through the gastrointestinal (GI) tract to assess GE and GI motility. SmartPill eliminates radiation exposure and is the only motility test that provides a complete transit profile of the GI tract.
Time frame: Baseline and Day 7
AUCτ: Area Under the Plasma Concentration-time Curve From 0 to Time (T) Over the Dosing Interval for TAK-906 in Part 1
Time frame: Part 1: Day 1 predose and at multiple timepoints, (Up to 8 hours) postdose and Day 7 predose and at multiple timepoints (Up to 48 hours) postdose
Cmax: Maximum Observed Plasma Concentration for TAK 906 in Part 1
Time frame: Part 1: Day 1 predose and at multiple timepoints, (Up to 8 hours) postdose and Day 7 predose and at multiple timepoints (Up to 48 hours) postdose
Ctrough: Observed Concentration at the End of a Dosing Interval for TAK-906 in Part 1
Time frame: Part 1: Predose on Days 2, 3, 4, 5, 6, 7, 8 and 9
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-906 in Part 1
Time frame: Part 1: Day 1 predose and at multiple timepoints, (Up to 8 hours) postdose and Day 7 predose and at multiple timepoints (Up to 48 hours) postdose
Participants took part in the study at 7 investigative sites in the United States from 26 September 2017 to 09 March 2018.
| Milestone | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Part 2: TAK-906 Maleate 25 mg Under Fed Conditions | Part 2: TAK-906 Maleate 25 mg Fasted Condition | Part 2: Metoclopramide 10 mg |
|---|---|---|---|---|---|---|---|
| Started | 12 | 14 | 12 | 13 | 0 | 0 | 0 |
| Completed | 11 | 14 | 12 | 11 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Part 2: TAK-906 Maleate 25 mg Under Fed Conditions | Part 2: TAK-906 Maleate 25 mg Fasted Condition | Part 2: Metoclopramide 10 mg |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 6 | 0 | 15 |
| Treated | 0 | 0 | 0 | 0 | 6 | 0 | 13 |
| Completed | 0 | 0 | 0 | 0 | 6 | 0 | 13 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Part 2: TAK-906 Maleate 25 mg Under Fed Conditions | Part 2: TAK-906 Maleate 25 mg Fasted Condition | Part 2: Metoclopramide 10 mg |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 6 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 6 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A SAE is an AE resulting in any of the following outcomes or deemed significant for any following reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event.
| Participants | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Part 2: TAK-906 Maleate 25 mg Fed Condition | Part 2: TAK-906 Maleate 25 mg Fasted Condition | Part 2: Metoclopramide 10 mg |
|---|---|---|---|---|---|---|---|
| TEAEs | 4 | 4 | 3 | 4 | 1 | 0 | 1 |
| SAEs | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
Clinical Laboratory parameters included tests for chemistry, hematology and urinalysis. Markedly abnormal values during treatment period were categorized as:alanine aminotransferase (ALT)\>3.0 U/L\*upper limit of normal(ULN),albumin\<25 g/L\*lower limit of normal(LLN),alkaline phosphatase \>3.0 U/L\*ULN,aspartate aminotransferase \>3.0 U/L\*ULN,bilirubin \>2 umol/L\*ULN,blood urea nitrogen(BUN) \>10.7 mmol/L,calcium \<1.75 mmol/L, \>2.88 mmol/L,chloride \<75 mmol/L, \>126 mmol/L,creatinine \>177umol/L,gamma glutamyl transferase (GGT) \>3 U/L\*ULN,glucose \<2.8 mmol/L, \>19.4 mmol/L,phosphate \<0.52 mmol/L, \>2.10 mmol/L,potassium\<3 mmol/L, \>6 mmol/L,sodium \<130 mmol/L, \>150 mmol/L,hematocrit (%) \<0.8\*LLN, \>1.2\*ULN,hemoglobin \<0.8 g/L\*LLN, \>1.2 g/L\*ULN,leukocytes \<0.5 (10\^9/L)\*LLN, \>1.5 (10\^9/L)\*ULN,erythrocytes\<0.8 (10\^12/L)\*LLN, \>1.2(10\^12/L)\*ULN,platelets \<75(10\^9/L), \>600(10\^9/L). Participants with at least 1 markedly abnormal laboratory parameter value is reported.
| Participants | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg |
|---|---|---|---|---|
| Hematocrit (%)<0.8 x LLN | 0 | 1 | 0 | 0 |
| Hemoglobin (g/L) <0.8 x LLN | 1 | 0 | 0 | 0 |
| ALT >3.0 U/Lx ULN | 0 | 0 | 1 | 0 |
| AST >3.0 U/L x ULN | 0 | 0 | 1 | 0 |
| BUN >10.7 mmol/L | 1 | 0 | 0 | 1 |
| Calcium >2.88 mmol/L | 0 | 0 | 0 | 1 |
| GGT >3 x ULN | 0 | 0 | 0 | 1 |
| Sodium (mmol/L) <130 mmol/L | 1 | 0 | 0 | 0 |
Vital signs included body temperature, diastolic and systolic blood pressure (mmHg), and heart rate (beats per minute \[bpm\]). Heart rate\<50 bpm and systolic blood pressure \<85 mmHg were considered markedly abnormal.
| Participants | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Part 2: TAK-906 Maleate 25 mg Fed Condition | Part 2: TAK-906 Maleate 25 mg Fasted Condition | Part 2: Metoclopramide 10 mg |
|---|---|---|---|---|---|---|---|
| Heart Rate (bpm) <50 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Systolic Blood Pressure (mmHg) <85 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
The 12-lead electrocardiogram (ECG) values outside the range Heart Rate \<50 (beats/min), PR Interval ≤120 (msec), PR Interval ≥200 (msec), QRS Duration ≥120 (msec), QT Interval ≥460 (msec) were considered markedly abnormal.
| Participants | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Part 2: TAK-906 Maleate 25 mg Fed Condition | Part 2: TAK-906 Maleate 25 mg Fasted Condition | Part 2: Metoclopramide 10 mg |
|---|---|---|---|---|---|---|---|
| Heart Rate (bpm) <50 | 1 | 1 | 0 | 0 | 1 | 1 | 0 |
| PR Interval (msec) ≤120 | 0 | 1 | 1 | 1 | 0 | 0 | 1 |
| PR Interval (msec) ≥200 | 1 | 2 | 1 | 4 | 0 | 0 | 4 |
| QRS Duration (msec) ≥120 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| QT Interval (msec) ≥460 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
Change in serum prolactin on Day 1 at the Tmax, time of first occurrence of maximum serum concentration (Cmax) relative to Baseline was calculated as a ratio of maximum serum prolactin concentration on Day 1 to serum prolactin concentration at Baseline.
| ratio | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg |
|---|---|---|---|---|
| Change From Baseline in Serum Prolactin Concentration on Day 1 at Tmax, Time of First Occurrence of Maximum Serum Concentration (Cmax) for TAK-906 Maleate for Part 1 | 1.54 ± 0.704 | 12.77 ± 9.102 | 19.92 ± 13.604 | 20.07 ± 9.170 |
The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE) in adults. The GEBT measures how fast solid food moves from the stomach to the small intestine during the digestive process and aids in the diagnosis of delayed stomach emptying (GP). GE half-emptying time is the time in minutes (min) for half of the ingested solids to leave the stomach. This value was measured by the 13C spirulina GEBT.
| min | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg |
|---|---|---|---|---|
| Baseline | 118.74 ± 43.106 | 130.18 ± 35.316 | 121.26 ± 33.606 | 122.50 ± 31.803 |
| Change from Baseline at Day 7 | 4.55 ± 16.332 | 6.21 ± 36.986 | 7.80 ± 52.946 | 7.72 ± 24.609 |
The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE) in adults. The GEBT measures how fast solid food moves from the stomach to the small intestine during the digestive process and aids in the diagnosis of delayed stomach emptying (GP). GE half-emptying time is the time in minutes (min) for half of the ingested solids to leave the stomach. This value was measured by the 13C spirulina GEBT.
| minute (min) | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg |
|---|---|---|---|---|
| Baseline | 118.74 ± 43.106 | 130.18 ± 35.316 | 121.26 ± 33.606 | 122.50 ± 31.803 |
| Change from Baseline at Day 1 | -5.71 ± 21.687 | 0.12 ± 21.736 | 6.74 ± 44.390 | 0.71 ± 21.192 |
SmartPill is an ingestible capsule that measures pressure, potential of hydrogen (pH) and temperature as it travels through the gastrointestinal (GI) tract to assess GE and GI motility. SmartPill eliminates radiation exposure and is the only motility test that provides a complete transit profile of the GI tract.
| percent change in GE time | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Gastric Emptying (GE) Time as Measured by the SmartPill on Day 7 for Part 1 | 124.62 ± 181.125 | 61.72 ± 195.867 | 419.27 ± 885.362 | 71.09 ± 121.584 |
| h*ng/mL | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg |
|---|---|---|---|
| Day 1 | 4.67 ± 1.69 | 23.0 ± 7.76 | 131 ± 44.8 |
| Day 7 | 5.46 ± 2.07 | 26.3 ± 11.3 | 166 ± 93.0 |
| ng/mL | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg |
|---|---|---|---|
| Day 1 | 2.27 ± 0.819 | 12.0 ± 5.36 | 75.7 ± 39.9 |
| Day 7 | 2.87 ± 1.78 | 15.5 ± 5.58 | 99.6 ± 69.4 |
| ng/mL | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg |
|---|---|---|---|
| Predose on Day 2 | 0.0121 ± 0.0315 | 0.262 ± 0.349 | 0.770 ± 0.513 |
| Predose on Day 3 | 0.0423 ± 0.0527 | 0.503 ± 0.640 | 0.958 ± 0.750 |
| Predose on Day 4 | 0.0178 ± 0.0503 | 0.302 ± 0.214 | 1.17 ± 0.799 |
| Predose on Day 5 | 0.0457 ± 0.0962 | 1.09 ± 1.97 | 1.95 ± 2.38 |
| Predose on Day 6 | 0.0423 ± 0.0502 | 0.412 ± 0.415 | 1.01 ± 0.469 |
| Predose on Day 7 | 0.0596 ± 0.0905 | 0.336 ± 0.383 | 1.48 ± 0.936 |
| Predose on Day 8 | 0.0763 ± 0.100 | 0.522 ± 0.648 | 1.16 ± 0.878 |
| Predose on Day 9 | 0.0700 ± 0.120 | 0.280 ± 0.243 | 1.40 ± 1.08 |
| hour (hr) | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg |
|---|---|---|---|
| Day 1 | 1.00 (0.48 to 2.00) | 1.00 (0.50 to 4.00) | 1.00 (0.50 to 2.00) |
| Day 7 | 1.00 (0.50 to 2.00) | 1.00 (0.50 to 1.52) | 0.98 (0.48 to 1.98) |
Collected over Baseline to 14 days after the last dose of study drug (Up to approximately 39 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Placebo | 0/12 (0%) | 1/12 (8.3%) | 3/12 (25%) |
| Part 1: TAK 906 Maleate 5 mg | 0/14 (0%) | 0/14 (0%) | 4/14 (28.6%) |
| Part 1: TAK 906 Maleate 25 mg | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Part 1: TAK 906 Maleate 100 mg | 0/13 (0%) | 1/13 (7.7%) | 4/13 (30.8%) |
| Part 2: TAK-906 Maleate 25 mg Fed Condition | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part 2: TAK-906 Maleate 25 mg Fasted Condition | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part 2: Metoclopramide 10 mg | 0/13 (0%) | 0/13 (0%) | 1/13 (7.7%) |
| Event | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Part 2: TAK-906 Maleate 25 mg Fed Condition | Part 2: TAK-906 Maleate 25 mg Fasted Condition | Part 2: Metoclopramide 10 mg |
|---|---|---|---|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 1/12 | 0/14 | 0/12 | 1/13 | 0/6 | 0/6 | 0/13 |
| Urinary tract infectionInfections and infestations | 0/12 | 0/14 | 0/12 | 1/13 | 0/6 | 0/6 | 0/13 |
| Event | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Part 2: TAK-906 Maleate 25 mg Fed Condition | Part 2: TAK-906 Maleate 25 mg Fasted Condition | Part 2: Metoclopramide 10 mg |
|---|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/12 | 1/14 | 0/12 | 0/13 | 1/6 | 0/6 | 0/13 |
| FatigueGeneral disorders | 0/12 | 2/14 | 0/12 | 0/13 | 0/6 | 0/6 | 0/13 |
| PalpitationsCardiac disorders | 0/12 | 0/14 | 1/12 | 0/13 | 0/6 | 0/6 | 0/13 |
| DiarrhoeaGastrointestinal disorders | 1/12 | 0/14 | 1/12 | 1/13 | 0/6 | 0/6 | 0/13 |
| Abdominal painGastrointestinal disorders | 1/12 | 0/14 | 0/12 | 0/13 | 0/6 | 0/6 | 0/13 |
| Abdominal pain upperGastrointestinal disorders | 1/12 | 0/14 | 0/12 | 0/13 | 0/6 | 0/6 | 0/13 |
| ConjunctivitisInfections and infestations | 1/12 | 0/14 | 0/12 | 0/13 | 0/6 | 0/6 | 0/13 |
| Liver function test increasedInvestigations | 0/12 | 0/14 | 1/12 | 1/13 | 0/6 | 0/6 | 0/13 |
| HeadacheNervous system disorders | 1/12 | 0/14 | 1/12 | 1/13 | 0/6 | 0/6 | 0/13 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/12 | 0/14 | 0/12 | 0/13 | 0/6 | 0/6 | 1/13 |
Safety analysis set (SAS), Part 1, included all participants who were randomized (Part 1) and received at least 1 dose of study drug.
| Age, Continuous(years) | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Total |
|---|---|---|---|---|---|
| Mean | 49.9 ± 13.84 | 54.7 ± 11.75 | 52.7 ± 17.13 | 55.9 ± 10.19 | 53.4 ± 13.14 |
| Sex: Female, Male(Participants) | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Total |
|---|---|---|---|---|---|
| Female | 9 | 11 | 10 | 10 | 40 |
| Male | 3 | 3 | 2 | 3 | 11 |
| Race/Ethnicity, Customized(Participants) | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 5 | 3 | 7 | 24 |
| Non-Hispanic and Latino | 3 | 9 | 9 | 6 | 27 |
| Race/Ethnicity, Customized(Participants) | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Total |
|---|---|---|---|---|---|
| Black or African American | 1 | 1 | 4 | 2 | 8 |
| White | 11 | 13 | 7 | 11 | 42 |
| Multiracial | 0 | 0 | 1 | 0 | 1 |
| Region of Enrollment(Participants) | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Total |
|---|---|---|---|---|---|
| United States | 12 | 14 | 12 | 13 | 51 |
| Height(cm) | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Total |
|---|---|---|---|---|---|
| Mean | 164.62 ± 9.790 | 163.95 ± 6.751 | 164.56 ± 7.204 | 164.93 ± 9.778 | 164.50 ± 8.212 |
| Weight(kg) | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Total |
|---|---|---|---|---|---|
| Mean | 74.70 ± 17.231 | 79.86 ± 13.470 | 80.55 ± 11.346 | 88.24 ± 11.803 | 80.95 ± 14.064 |
| Body Mass Index (BMI)(kg/m^2) | Part 1: Placebo | Part 1: TAK 906 Maleate 5 mg | Part 1: TAK 906 Maleate 25 mg | Part 1: TAK 906 Maleate 100 mg | Total |
|---|---|---|---|---|---|
| Mean | 27.282 ± 4.2276 | 29.679 ± 4.5043 | 29.832 ± 4.5461 | 32.565 ± 4.4001 | 29.887 ± 4.6805 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2017 to primary completion in Mar 2018, 5 months.
Results were first posted in Jul 2019, 1 year 4 months after primary completion.
Of 65 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 5 months is below that.
Counting every sponsor, half of 147 studies reached it within 27 months; a quarter within 12 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trazpiroben
Millennium Pharmaceuticals, Inc. →